Soligenix Inc. provided a business update highlighting recent progress and upcoming milestones. As of September 30, 2025, the company reported approximately $10.5 million in cash, not including an additional $500,000 in non-dilutive funding from New Jersey's net operating loss (NOL) sales program. Soligenix remains focused on advancing its Specialized BioTherapeutics rare disease business segment, particularly the completion of its confirmatory Phase 3 HyBryte™ clinical trial. The company anticipates achieving multiple key milestones through 2026 and continues to evaluate strategic options, including partnership and merger and acquisition opportunities. Additionally, Soligenix is pursuing ex-U.S. market partnerships and exploring other potential indications for its synthetic hypericin platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH86244) on February 12, 2026, and is solely responsible for the information contained therein.